Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Study results show that responses were durable and deepened over time – 58 percent of patients receiving teclistamab achieved a very good partial response (VGPR) or better, and 40 percent achieved a complete response (CR) or better at the RP2D.
Product Name : JNJ-64007957
Product Type : Antibody
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : Ponesimod
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Approves PONVORYTM for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis
Details : Within the OPTIMUM study, overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation.
Product Name : Ponvory
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : Ponesimod
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daratumumab,Bortezomib,Cyclophosphamide
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Positive CHMP Opinion for daratumumab SC in combination with Pd in the treatment of MM is supported by data from the Phase 3 APOLLO study conducted in collaboration with the European Myeloma Network.
Product Name : Darzalex
Product Type : Antibody
Upfront Cash : Inapplicable
May 21, 2021
Lead Product(s) : Daratumumab,Bortezomib,Cyclophosphamide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Janssen Seeks EU Approval for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-Cel)
Details : The application is supported by positive results from the ongoing Phase 1b/2 CARTITUDE-1 study, investigating the safety and efficacy of Cilta-Cel.
Product Name : Cilta-cel
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 30, 2021
Reset All
